Summary

The global Nitinol Revascularization Device market is projected to grow from US$ 2611 million in 2025 to US$ 4017 million by 2032, at a CAGR of 6.0% (2026-2032), driven by critical product segments and diverse end‑use applications.
Nitinol Revascularization Devices are catheter-delivered interventional devices that use nickel-titanium alloy as the principal material of their therapeutic scaffold, mesh or retrieval structure to restore or maintain blood flow in narrowed or occluded arteries. They use the superelasticity and shape-recovery properties of nitinol to provide permanent vascular support, capture and remove thrombus, or temporarily expand a narrowed vessel before retrieval. Product forms include arterial stents, drug-eluting stents, stent grafts used for occlusive arterial disease, stent retrievers and temporary dilation devices. Laser-cut and braided frameworks are combined with dedicated delivery systems, radiopaque markers and controlled deployment mechanisms to accommodate different vessel diameters, anatomical configurations and treatment requirements. Principal applications include peripheral artery disease, carotid artery disease, acute ischemic stroke and selected other arterial conditions requiring restoration of blood flow.
Key Findings
The Nitinol Revascularization Device market comprises permanent support devices and retrievable devices serving distinct arterial treatment functions
The Nitinol Revascularization Device market uses laser-cut and braided frameworks across permanent implantation and temporary intervention products
Nitinol Revascularization Device applications include peripheral arterial support carotid revascularization and intracranial thrombus retrieval
Nitinol Revascularization Device purchasing decisions depend on anatomical suitability clinical evidence delivery performance and supply reliability
Market Trends
Product development is moving toward more anatomy-specific structures and greater control throughout delivery, deployment and retrieval. Permanent support devices must balance radial support, flexibility and fatigue resistance, while retrieval devices require dependable clot engagement and controlled interaction with the vessel wall. Improved radiopacity and lower-profile delivery systems help physicians assess device behavior and reach challenging anatomy, although smaller profiles must remain compatible with structural durability and therapeutic performance. Drug delivery and surface modification provide additional differentiation in selected implantable products, while adjustable and specialized mesh designs broaden the engineering options for temporary interventions. Across these developments, nitinol is an enabling material rather than a sufficient measure of product quality. Commercial differentiation increasingly depends on how the complete device performs within a defined procedure, supported by manufacturing consistency, clinical evidence and compatibility with accompanying interventional tools.
Market Dynamics
Drivers
Demand is supported by the clinical need to restore perfusion in patients with arterial stenosis or occlusion and by the development of hospital capabilities to deliver endovascular treatment. Peripheral vascular services, stroke treatment networks and referral pathways influence how many eligible patients reach intervention and which devices are used. Nitinol's capacity to recover its shape after compression supports catheter-based delivery and structures that accommodate demanding vascular anatomy. Within established treatment pathways, additional demand can arise from broader access to qualified centers, improved diagnosis and the treatment of more complex cases. Device consumption nevertheless depends on procedure selection and product use rather than disease prevalence alone. Growth therefore rests on the combination of accessible clinical infrastructure, appropriate patient selection, dependable product performance and purchasing arrangements that make treatment economically practicable.
Restraints
Adoption is constrained by treatment costs, procedural complexity and the need to match device characteristics to individual lesions. Calcification, tortuosity, vessel movement and differences in thrombus composition can limit the suitability of a particular structure, preventing a single platform from serving all cases. Permanent implants also face competition from treatment strategies that seek to minimize the amount of material left in the vessel, while stent retrievers compete and cooperate with aspiration-based approaches. Procurement pressure can reduce realized prices even when procedure volumes increase. Manufacturers must also fund clinical evaluation, regulatory maintenance, physician training and specialized production capabilities. These requirements create a gap between technical feasibility and profitable commercialization: a product must deliver sufficient clinical and operational value to justify its place within an existing treatment pathway and hospital budget.
Opportunities
Commercial opportunities are concentrated in products that address identifiable procedural limitations. More conformable support structures, predictable release mechanisms and improved delivery through difficult anatomy can support entry into additional accounts or treatment settings. Retrieval products can create value through better interaction with different clot characteristics and reliable compatibility with aspiration and access systems. Local manufacturing and regional service capabilities offer opportunities where registration, training and supply continuity constrain access. Portfolio expansion can also strengthen a supplier's position when complementary products simplify procurement or support established procedural workflows. These opportunities require application-specific evidence and a clear route to reimbursement and purchasing approval. Smaller vessel sizes, additional anatomical locations and novel treatment functions should therefore be treated as distinct commercial development programs, with their own validation requirements, rather than automatic extensions of an existing product's addressable market.
Challenges
The principal long-term challenge is maintaining clinical and manufacturing reliability while expanding product variety and geographic reach. Changes to framework geometry, processing conditions, surface treatment or delivery components can affect mechanical behavior and require additional validation. A product approved in one jurisdiction may face different evidence, labeling and quality requirements elsewhere, increasing the cost of international commercialization. Competitive pressure also comes from improvements in alternative treatment methods and from incumbent suppliers with established clinical relationships and broad portfolios. Recalls, interrupted supply or inconsistent product performance can weaken hospital confidence and delay adoption beyond the immediate affected period. Sustainable participation therefore requires disciplined change control, traceability, post-market surveillance and investment in technical support. Commercial expansion must remain aligned with these capabilities so that wider distribution does not outpace the manufacturer's ability to maintain product quality and service.
Industry Chain Analysis
The upstream supply chain includes medical-grade nitinol tubing and wire, radiopaque materials, polymers, coating inputs and components for delivery systems. Material composition, cleanliness, dimensional consistency and mechanical properties influence downstream process stability and finished-device performance. Midstream activities include structural design, laser cutting or braiding, shape setting, joining, electropolishing, surface treatment, assembly, sterilization and packaging. Value is created through the integration and validation of these processes, particularly where small changes in geometry or processing affect radial behavior, fatigue resistance or retrieval performance. Downstream participants include registration holders, distributors, procurement organizations and hospitals, with clinical training and technical service supporting adoption. Raw material capability alone does not establish a competitive finished-device business. Product design, manufacturing yield, quality assurance, clinical evidence and market access collectively determine the value captured, while sales volume, product mix and channel arrangements influence how development and operating costs are recovered.
Segment Insights
The Nitinol Revascularization Device permanent support segment addresses the sustained maintenance of arterial patency. Its products differ in framework design and therapeutic features, with demand shaped by the target vessel's mechanical environment and the lesion being treated. Bare, drug-eluting and covered configurations offer different clinical functions within this segment, while deployment accuracy, conformability and durability remain important purchasing considerations. The thrombus retrieval segment serves a different task: engaging and removing clot while allowing the device to be withdrawn. Its commercial value depends on deliverability, clot retention, vessel interaction and compatibility with the wider thrombectomy procedure. Temporary dilation is a separate functional segment directed toward reversible vessel expansion in selected indications. Across all three segments, laser-cut and braided construction and maximum expanded diameter provide additional ways to assess product suitability. Diameter should be considered alongside working length, structural behavior and delivery compatibility; a smaller or larger specification is valuable only when it addresses a defined clinical requirement.
Downstream Market Opportunities
Peripheral artery disease, carotid artery disease and acute ischemic stroke provide distinct purchasing and product-development opportunities. In peripheral interventions, vascular teams evaluate support, flexibility and durability under vessel movement, creating opportunities for structures suited to specific lesion lengths and anatomical demands. Carotid applications place particular emphasis on accurate positioning, vessel conformity and management of plaque-related embolic risk, making framework and mesh characteristics commercially relevant. In acute ischemic stroke, neurointerventional teams assess rapid delivery, clot engagement, retrieval behavior and compatibility with aspiration catheters and other access devices. Hospital procurement decisions also incorporate registration status, supply continuity, training and total procedural cost. Suppliers can expand through new hospital accounts, additional specifications and stronger local support, but these routes depend on demonstrated usefulness within the relevant workflow. Coronary retrieval and temporary dilation provide more specialized opportunities whose adoption must follow the applicable indications and clinical requirements.
Regional Insights
Regional differences reflect treatment infrastructure, purchasing systems, regulatory pathways and the availability of trained interventionists. North America and Europe combine established vascular treatment services with substantial requirements for clinical evidence, quality assurance and post-market support. Commercial access in these regions depends on hospital relationships, reimbursement and the ability to demonstrate value against existing treatment choices. China's market combines domestic manufacturing development with procurement pressure and demand for wider treatment access, making cost control, reliable production and clinical service important competitive factors. Japan requires close alignment with local registration, distribution and clinical practice, with manufacturing responsibility distinguished from sales representation. India and Southeast Asia offer opportunities linked to the development of specialist centers and distribution networks, although purchasing capacity and service availability vary across markets. Regional expansion is therefore best approached through specific registration, account-development and support plans, with production location assessed separately from headquarters and sales destination.
Competitive Landscape Analysis
Competition is organized primarily around clinical product groups rather than the use of nitinol alone. Diversified suppliers such as Medtronic, Boston Scientific and Abbott combine arterial support platforms with broader interventional portfolios and established commercial networks. Stryker, Johnson & Johnson and specialist manufacturers compete in retrieval through framework design, delivery characteristics and integration with thrombectomy workflows. Chinese participants including Zylox-Tonbridge, MicroPort NeuroScientific, Peijia Medical and other specialist manufacturers add domestic production and product-development capabilities, while regional stent manufacturers contribute additional structural and therapeutic options. Corporate transactions are also reshaping supply: Teleflex's acquisition of the relevant BIOTRONIK vascular intervention business and Zylox-Tonbridge's acquisition of a controlling interest in Optimed connect product portfolios with different manufacturing and distribution platforms. Durable advantages depend on the combined strength of clinical evidence, design, production consistency, registration coverage and service. Neither a broad catalog nor a novel framework alone guarantees sustained adoption without reliable performance and a viable commercial delivery model.
Report Scope
This definitive report equips business leaders, decision-makers, and stakeholders with a 360° view of the global Nitinol Revascularization Device market, seamlessly integrating production and sales performance across the value chain. It analyzes historical sales volume and revenue sales data (2021–2025) and delivers forecasts through 2032, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies volume and value, growth rates, technical innovations, niche opportunities, and substitution risks, and analyzes downstream customer distribution pattern.
Granular regional insights cover five major markets (North America, Europe, APAC, South America, and MEA) with in‑depth analysis of 20+ countries. Each region’s dominant products, competitive landscape, and downstream demand trends are clearly detailed.
Critical competitive intelligence profiles manufacturers (sales volume, revenue, margins, pricing strategies, and major customers) and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise supply‑chain overview maps upstream suppliers, manufacturing technologies, cost structures, and distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
Medtronic
Boston Scientific
Abbott
BD
Cook Medical
W. L. Gore & Associates
Cordis
Teleflex
Terumo
Otsuka Holdings
Stryker
Johnson & Johnson
Acandis
Rapid Medical
Vesalio
Wallaby Medical
iVascular
Alvimedica
Balton
Meril Life Sciences
InspireMD
Gravity Medical Technology
Zylox-Tonbridge Medical Technology
MicroPort Scientific
MicroPort NeuroScientific
Peijia Medical
Skynor Medical
Suzhou Zenith Vascular
TJWY Medical
Segment by Type
Laser-cut
Braided
Other
Segment by Product Function
Permanent Support
Thrombus Retrieval
Temporary Dilation
Other
Segment by Maximum Expanded Diameter
≤4 mm
>4–6 mm
>6–8 mm
>8 mm
Segment by Application
Peripheral Artery Disease
Carotid Artery Disease
Acute Ischemic Stroke
Coronary Artery Disease
Other
Sales by Region
North America
U.S.
Canada
Mexico
Asia-Pacific
China
Japan
South Korea
India
China Taiwan
Southeast Asia (Indonesia, Vietnam, Thailand)
Europe
Germany
France
U.K.
Italy
Russia
Central and South America
Brazil
Argentina
Rest of Central and South America
Middle East, Africa
Turkey
Egypt
GCC Countries
South Africa
Chapter Outline
Chapter 1: Defines the Nitinol Revascularization Device study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential
Chapter 2: Offers current market state, projects global revenue and sales to 2032, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the manufacturer landscape: ranks by volume and revenue, analyzes profitability and pricing, maps production bases, details manufacturer performance by product type and evaluates concentration alongside M&A moves
Chapter 4: Unlocks high margin product segments: compares sales, revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities: evaluates sales, revenue, and pricing by Application, identifies emerging use cases, and profiles leading customers by region and by Application
Chapter 6: North America: breaks down sales and revenue by Application and country, profiles key manufacturers and assesses growth drivers and barriers
Chapter 7: Europe: analyses regional sales, revenue and market by Application and manufacturers, flagging drivers and barriers
Chapter 8: Asia Pacific: quantifies sales and revenue by Application, and region/country, profiles top manufacturers, and uncovers high potential expansion areas
Chapter 9: Central & South America: measures sales and revenue by Application, and country, profiles top manufacturers, and identifies investment opportunities and challenges
Chapter 10: Middle East and Africa: evaluates sales and revenue by Application, and country, profiles key manufacturers, and outlines investment prospects and market hurdles
Chapter 11: Profiles manufacturers in depth: details product specs, sales, revenue, margins; top manufactures 2025 sales breakdowns by product type, by Application, by sales region SWOT analysis, and recent strategic developments
Chapter 12: Supply chain: analyses upstream raw materials and suppliers, manufacturing footprint, regional production and cost, regulatory and technology, plus downstream channels and distributor roles
Chapter 13: Market dynamics: explores drivers, restraints, regulatory impacts, and risk mitigation strategies
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report
Beyond standard market data, this analysis provides a clear profitability roadmap, empowering you to:
Allocate capital strategically to high growth regions (Chapters 6-10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Secure your supply chain against disruptions through upstream and downstream visibility (Chapters 12 and 13).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.

ページTOPに戻る

Table of Contents

1 Study Coverage
1.1 Introduction to Nitinol Revascularization Device: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global Nitinol Revascularization Device Market Size by Type, 2021 vs 2025 vs 2032
1.2.2 Laser-cut
1.2.3 Braided
1.2.4 Other
1.3 Market Segmentation by Product Function
1.3.1 Global Nitinol Revascularization Device Market Size by Product Function, 2021 vs 2025 vs 2032
1.3.2 Permanent Support
1.3.3 Thrombus Retrieval
1.3.4 Temporary Dilation
1.3.5 Other
1.4 Market Segmentation by Maximum Expanded Diameter
1.4.1 Global Nitinol Revascularization Device Market Size by Maximum Expanded Diameter, 2021 vs 2025 vs 2032
1.4.2 ≤4 mm
1.4.3 >4–6 mm
1.4.4 >6–8 mm
1.4.5 >8 mm
1.5 Market Segmentation by Application
1.5.1 Global Nitinol Revascularization Device Market Size by Application, 2021 vs 2025 vs 2032
1.5.2 Peripheral Artery Disease
1.5.3 Carotid Artery Disease
1.5.4 Acute Ischemic Stroke
1.5.5 Coronary Artery Disease
1.5.6 Other
1.6 Assumptions and Limitations
1.7 Study Objectives
1.8 Years Considered

2 Executive Summary
2.1 Global Nitinol Revascularization Device Revenue Estimates and Forecasts (2021-2032)
2.2 Global Nitinol Revascularization Device Revenue by Region
2.2.1 Revenue Comparison: 2021 vs 2025 vs 2032
2.2.2 Historical and Forecasted Revenue by Region (2021-2032)
2.2.3 Global Revenue-Based Market Share by Region (2021-2032)
2.3 Global Nitinol Revascularization Device Sales Estimates and Forecasts (2021-2032)
2.4 Global Nitinol Revascularization Device Sales by Region
2.4.1 Sales Comparison: 2021 vs 2025 vs 2032
2.4.2 Historical and Forecasted Sales by Region (2021-2032)
2.4.3 Emerging Market Focus: Growth Drivers & Investment Trends
2.4.4 Global Sales Market Share by Region (2021-2032)

3 Competitive Landscape
3.1 Global Nitinol Revascularization Device Sales by Manufacturers
3.1.1 Global Sales Volume by Manufacturers (2021-2026)
3.1.2 Global Top 5 and Top 10 Manufacturers’Market Share by Sales Volume (2025)
3.2 Global Nitinol Revascularization Device Manufacturer Revenue Rankings and Tiers
3.2.1 Global Revenue (Value) by Manufacturers (2021-2026)
3.2.2 Global Key Manufacturer Revenue Ranking (2024 vs. 2025)
3.2.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.3 Manufacturer Profitability Profiles and Pricing Strategies
3.3.1 Gross Margin by Top Manufacturer (2021 vs 2025)
3.3.2 Manufacturer-Level Price Trends (2021-2026)
3.4 Key Manufacturers Manufacturing Base and Headquarters
3.5 Key Manufacturers Market Share by Product Type
3.5.1 Laser-cut: Market Share by Key Manufacturers
3.5.2 Braided: Market Share by Key Manufacturers
3.5.3 Other: Market Share by Key Manufacturers
3.6 Global Nitinol Revascularization Device Market Concentration and Dynamics
3.6.1 Global Market Concentration
3.6.2 Entrant/Exit Impact Analysis
3.6.3 Strategic Moves: M&A, Capacity Expansion, R&D Investment

4 Product Segmentation
4.1 Global Nitinol Revascularization Device Sales Performance by Type
4.1.1 Global Nitinol Revascularization Device Sales Volume by Type (2021-2032)
4.1.2 Global Nitinol Revascularization Device Revenue by Type (2021-2032)
4.1.3 Global Average Selling Price (ASP) Trends by Type (2021-2032)
4.2 Global Nitinol Revascularization Device Sales Performance by Product Function
4.2.1 Global Nitinol Revascularization Device Sales Volume by Product Function (2021-2032)
4.2.2 Global Nitinol Revascularization Device Revenue by Product Function (2021-2032)
4.2.3 Global Average Selling Price (ASP) Trends by Product Function (2021-2032)
4.3 Global Nitinol Revascularization Device Sales Performance by Maximum Expanded Diameter
4.3.1 Global Nitinol Revascularization Device Sales Volume by Maximum Expanded Diameter (2021-2032)
4.3.2 Global Nitinol Revascularization Device Revenue by Maximum Expanded Diameter (2021-2032)
4.3.3 Global Average Selling Price (ASP) Trends by Maximum Expanded Diameter (2021-2032)
4.4 Product Technology Differentiation
4.5 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.5.1 High-Growth Niches and Adoption Drivers
4.5.2 Profitability Hotspots and Cost Drivers
4.5.3 Substitution Threats

5 Downstream Applications and Customers
5.1 Global Nitinol Revascularization Device Sales by Application
5.1.1 Global Historical and Forecasted Sales by Application (2021-2032)
5.1.2 Global Sales Market Share by Application (2021-2032)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Global Nitinol Revascularization Device Revenue by Application
5.2.1 Global Historical and Forecasted Revenue by Application (2021-2032)
5.2.2 Revenue-Based Market Share by Application (2021-2032)
5.3 Global Pricing Dynamics by Application (2021-2032)
5.4 Downstream Customer Analysis
5.4.1 Top Customers by Region
5.4.2 Top Customers by Application

6 North America
6.1 North America Sales Volume and Revenue (2021-2032)
6.2 North America Key Manufacturers Sales Revenue in 2025
6.3 North America Nitinol Revascularization Device Sales and Revenue by Application (2021-2032)
6.4 North America Growth Accelerators and Market Barriers
6.5 North America Nitinol Revascularization Device Market Size by Country
6.5.1 North America Revenue by Country
6.5.2 North America Sales Trends by Country
6.5.3 US
6.5.4 Canada
6.5.5 Mexico

7 Europe
7.1 Europe Sales Volume and Revenue (2021-2032)
7.2 Europe Key Manufacturers Sales Revenue in 2025
7.3 Europe Nitinol Revascularization Device Sales and Revenue by Application (2021-2032)
7.4 Europe Growth Accelerators and Market Barriers
7.5 Europe Nitinol Revascularization Device Market Size by Country
7.5.1 Europe Revenue by Country
7.5.2 Europe Sales Trends by Country
7.5.3 Germany
7.5.4 France
7.5.5 U.K.
7.5.6 Italy
7.5.7 Russia

8 Asia-Pacific
8.1 Asia-Pacific Sales Volume and Revenue (2021-2032)
8.2 Asia-Pacific Key Manufacturers Sales Revenue in 2025
8.3 Asia-Pacific Nitinol Revascularization Device Sales and Revenue by Application (2021-2032)
8.4 Asia-Pacific Nitinol Revascularization Device Market Size by Region
8.4.1 Asia-Pacific Revenue by Region
8.4.2 Asia-Pacific Sales Trends by Region
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Southeast Asia
8.6.1 Southeast Asia Revenue by Country (2021 vs 2025 vs 2032)
8.6.2 Key Country Analysis: Indonesia, Vietnam, Thailand, Malaysia, Philippines
8.7 China
8.8 Japan
8.9 South Korea
8.10 China Taiwan
8.11 India

9 Central and South America
9.1 Central and South America Sales Volume and Revenue (2021-2032)
9.2 Central and South America Key Manufacturers Sales Revenue in 2025
9.3 Central and South America Nitinol Revascularization Device Sales and Revenue by Application (2021-2032)
9.4 Central and South America Investment Opportunities and Key Challenges
9.5 Central and South America Nitinol Revascularization Device Market Size by Country
9.5.1 Central and South America Revenue Trends by Country (2021 vs 2025 vs 2032)
9.5.2 Brazil
9.5.3 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Sales Volume and Revenue (2021-2032)
10.2 Middle East and Africa Key Manufacturers Sales Revenue in 2025
10.3 Middle East and Africa Nitinol Revascularization Device Sales and Revenue by Application (2021-2032)
10.4 Middle East and Africa Investment Opportunities and Key Challenges
10.5 Middle East and Africa Nitinol Revascularization Device Market Size by Country
10.5.1 Middle East and Africa Revenue Trends by Country (2021 vs 2025 vs 2032)
10.5.2 GCC Countries
10.5.3 Turkey
10.5.4 Egypt
10.5.5 South Africa

11 Corporate Profile
11.1 Medtronic
11.1.1 Medtronic Corporation Information
11.1.2 Medtronic Business Overview
11.1.3 Medtronic Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.1.4 Medtronic Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.1.5 Medtronic Nitinol Revascularization Device Sales by Product in 2025
11.1.6 Medtronic Nitinol Revascularization Device Sales by Application in 2025
11.1.7 Medtronic Nitinol Revascularization Device Sales by Geographic Area in 2025
11.1.8 Medtronic Nitinol Revascularization Device SWOT Analysis
11.1.9 Medtronic Recent Developments
11.2 Boston Scientific
11.2.1 Boston Scientific Corporation Information
11.2.2 Boston Scientific Business Overview
11.2.3 Boston Scientific Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.2.4 Boston Scientific Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.2.5 Boston Scientific Nitinol Revascularization Device Sales by Product in 2025
11.2.6 Boston Scientific Nitinol Revascularization Device Sales by Application in 2025
11.2.7 Boston Scientific Nitinol Revascularization Device Sales by Geographic Area in 2025
11.2.8 Boston Scientific Nitinol Revascularization Device SWOT Analysis
11.2.9 Boston Scientific Recent Developments
11.3 Abbott
11.3.1 Abbott Corporation Information
11.3.2 Abbott Business Overview
11.3.3 Abbott Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.3.4 Abbott Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.3.5 Abbott Nitinol Revascularization Device Sales by Product in 2025
11.3.6 Abbott Nitinol Revascularization Device Sales by Application in 2025
11.3.7 Abbott Nitinol Revascularization Device Sales by Geographic Area in 2025
11.3.8 Abbott Nitinol Revascularization Device SWOT Analysis
11.3.9 Abbott Recent Developments
11.4 BD
11.4.1 BD Corporation Information
11.4.2 BD Business Overview
11.4.3 BD Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.4.4 BD Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.4.5 BD Nitinol Revascularization Device Sales by Product in 2025
11.4.6 BD Nitinol Revascularization Device Sales by Application in 2025
11.4.7 BD Nitinol Revascularization Device Sales by Geographic Area in 2025
11.4.8 BD Nitinol Revascularization Device SWOT Analysis
11.4.9 BD Recent Developments
11.5 Cook Medical
11.5.1 Cook Medical Corporation Information
11.5.2 Cook Medical Business Overview
11.5.3 Cook Medical Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.5.4 Cook Medical Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.5.5 Cook Medical Nitinol Revascularization Device Sales by Product in 2025
11.5.6 Cook Medical Nitinol Revascularization Device Sales by Application in 2025
11.5.7 Cook Medical Nitinol Revascularization Device Sales by Geographic Area in 2025
11.5.8 Cook Medical Nitinol Revascularization Device SWOT Analysis
11.5.9 Cook Medical Recent Developments
11.6 W. L. Gore & Associates
11.6.1 W. L. Gore & Associates Corporation Information
11.6.2 W. L. Gore & Associates Business Overview
11.6.3 W. L. Gore & Associates Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.6.4 W. L. Gore & Associates Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.6.5 W. L. Gore & Associates Recent Developments
11.7 Cordis
11.7.1 Cordis Corporation Information
11.7.2 Cordis Business Overview
11.7.3 Cordis Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.7.4 Cordis Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.7.5 Cordis Recent Developments
11.8 Teleflex
11.8.1 Teleflex Corporation Information
11.8.2 Teleflex Business Overview
11.8.3 Teleflex Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.8.4 Teleflex Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.8.5 Teleflex Recent Developments
11.9 Terumo
11.9.1 Terumo Corporation Information
11.9.2 Terumo Business Overview
11.9.3 Terumo Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.9.4 Terumo Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.9.5 Terumo Recent Developments
11.10 Otsuka Holdings
11.10.1 Otsuka Holdings Corporation Information
11.10.2 Otsuka Holdings Business Overview
11.10.3 Otsuka Holdings Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.10.4 Otsuka Holdings Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.10.5 Otsuka Holdings Recent Developments
11.11 Stryker
11.11.1 Stryker Corporation Information
11.11.2 Stryker Business Overview
11.11.3 Stryker Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.11.4 Stryker Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.11.5 Stryker Recent Developments
11.12 Johnson & Johnson
11.12.1 Johnson & Johnson Corporation Information
11.12.2 Johnson & Johnson Business Overview
11.12.3 Johnson & Johnson Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.12.4 Johnson & Johnson Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.12.5 Johnson & Johnson Recent Developments
11.13 Acandis
11.13.1 Acandis Corporation Information
11.13.2 Acandis Business Overview
11.13.3 Acandis Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.13.4 Acandis Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.13.5 Acandis Recent Developments
11.14 Rapid Medical
11.14.1 Rapid Medical Corporation Information
11.14.2 Rapid Medical Business Overview
11.14.3 Rapid Medical Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.14.4 Rapid Medical Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.14.5 Rapid Medical Recent Developments
11.15 Vesalio
11.15.1 Vesalio Corporation Information
11.15.2 Vesalio Business Overview
11.15.3 Vesalio Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.15.4 Vesalio Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.15.5 Vesalio Recent Developments
11.16 Wallaby Medical
11.16.1 Wallaby Medical Corporation Information
11.16.2 Wallaby Medical Business Overview
11.16.3 Wallaby Medical Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.16.4 Wallaby Medical Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.16.5 Wallaby Medical Recent Developments
11.17 iVascular
11.17.1 iVascular Corporation Information
11.17.2 iVascular Business Overview
11.17.3 iVascular Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.17.4 iVascular Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.17.5 iVascular Recent Developments
11.18 Alvimedica
11.18.1 Alvimedica Corporation Information
11.18.2 Alvimedica Business Overview
11.18.3 Alvimedica Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.18.4 Alvimedica Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.18.5 Alvimedica Recent Developments
11.19 Balton
11.19.1 Balton Corporation Information
11.19.2 Balton Business Overview
11.19.3 Balton Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.19.4 Balton Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.19.5 Balton Recent Developments
11.20 Meril Life Sciences
11.20.1 Meril Life Sciences Corporation Information
11.20.2 Meril Life Sciences Business Overview
11.20.3 Meril Life Sciences Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.20.4 Meril Life Sciences Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.20.5 Meril Life Sciences Recent Developments
11.21 InspireMD
11.21.1 InspireMD Corporation Information
11.21.2 InspireMD Business Overview
11.21.3 InspireMD Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.21.4 InspireMD Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.21.5 InspireMD Recent Developments
11.22 Gravity Medical Technology
11.22.1 Gravity Medical Technology Corporation Information
11.22.2 Gravity Medical Technology Business Overview
11.22.3 Gravity Medical Technology Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.22.4 Gravity Medical Technology Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.22.5 Gravity Medical Technology Recent Developments
11.23 Zylox-Tonbridge Medical Technology
11.23.1 Zylox-Tonbridge Medical Technology Corporation Information
11.23.2 Zylox-Tonbridge Medical Technology Business Overview
11.23.3 Zylox-Tonbridge Medical Technology Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.23.4 Zylox-Tonbridge Medical Technology Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.23.5 Zylox-Tonbridge Medical Technology Recent Developments
11.24 MicroPort Scientific
11.24.1 MicroPort Scientific Corporation Information
11.24.2 MicroPort Scientific Business Overview
11.24.3 MicroPort Scientific Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.24.4 MicroPort Scientific Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.24.5 MicroPort Scientific Recent Developments
11.25 MicroPort NeuroScientific
11.25.1 MicroPort NeuroScientific Corporation Information
11.25.2 MicroPort NeuroScientific Business Overview
11.25.3 MicroPort NeuroScientific Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.25.4 MicroPort NeuroScientific Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.25.5 MicroPort NeuroScientific Recent Developments
11.26 Peijia Medical
11.26.1 Peijia Medical Corporation Information
11.26.2 Peijia Medical Business Overview
11.26.3 Peijia Medical Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.26.4 Peijia Medical Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.26.5 Peijia Medical Recent Developments
11.27 Skynor Medical
11.27.1 Skynor Medical Corporation Information
11.27.2 Skynor Medical Business Overview
11.27.3 Skynor Medical Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.27.4 Skynor Medical Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.27.5 Skynor Medical Recent Developments
11.28 Suzhou Zenith Vascular
11.28.1 Suzhou Zenith Vascular Corporation Information
11.28.2 Suzhou Zenith Vascular Business Overview
11.28.3 Suzhou Zenith Vascular Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.28.4 Suzhou Zenith Vascular Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.28.5 Suzhou Zenith Vascular Recent Developments
11.29 TJWY Medical
11.29.1 TJWY Medical Corporation Information
11.29.2 TJWY Medical Business Overview
11.29.3 TJWY Medical Nitinol Revascularization Device Product Models, Descriptions and Specifications
11.29.4 TJWY Medical Nitinol Revascularization Device Sales, Price, Revenue and Gross Margin (2021-2026)
11.29.5 TJWY Medical Recent Developments

12 Value Chain and Supply-Chain Analysis
12.1 Nitinol Revascularization Device Industry Chain
12.2 Nitinol Revascularization Device Upstream Materials Analysis
12.2.1 Raw Materials
12.2.2 Key Suppliers Market Share & Risk Assessment
12.3 Nitinol Revascularization Device Integrated Production Analysis
12.3.1 Manufacturing Footprint Analysis
12.3.2 Regional Production Market Share (2021-2032)
12.3.3 Regulatory and Trade Policy Impact on Production
12.3.4 Production Technology Overview
12.3.5 Regional Cost Drivers
12.4 Nitinol Revascularization Device Sales Channels and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors

13 Nitinol Revascularization Device Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
13.4 Impact of U.S. Tariffs

14 Key Findings in the Global Nitinol Revascularization Device Study

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details

ページTOPに戻る

List of Tables/Graphs

List of Tables
Table 1. Global Nitinol Revascularization Device Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Table 2. Global Nitinol Revascularization Device Market Size Growth Rate by Product Function, 2021 vs 2025 vs 2032 (US$ Million)
Table 3. Global Nitinol Revascularization Device Market Size Growth Rate by Maximum Expanded Diameter, 2021 vs 2025 vs 2032 (US$ Million)
Table 4. Global Nitinol Revascularization Device Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Table 5. Global Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 6. Global Nitinol Revascularization Device Revenue by Region (US$ Million), 2021-2026
Table 7. Global Nitinol Revascularization Device Revenue by Region (US$ Million), 2027-2032
Table 8. Global Nitinol Revascularization Device Sales Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Table 9. Global Nitinol Revascularization Device Sales by Region (K Units), 2021-2026
Table 10. Global Nitinol Revascularization Device Sales by Region (K Units), 2027-2032
Table 11. Emerging Market Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 12. Global Nitinol Revascularization Device Sales by Manufacturers (K Units), 2021-2026
Table 13. Global Nitinol Revascularization Device Sales Share by Manufacturers (2021-2026)
Table 14. Global Nitinol Revascularization Device Revenue by Manufacturers (US$ Million), 2021-2026
Table 15. Global Nitinol Revascularization Device Revenue-Based Market Share by Manufacturers (2021-2026)
Table 16. Global Key Manufacturers’Ranking Shift (2024 vs. 2025) (Based on Revenue)
Table 17. Global Manufacturer by Tier (Tier 1, Tier 2, and Tier 3), based on Nitinol Revascularization Device Revenue, 2025
Table 18. Global Nitinol Revascularization Device Average Gross Margin (%) by Manufacturer (2021 vs 2025)
Table 19. Global Nitinol Revascularization Device Average Selling Price (ASP) by Manufacturers (US$/Unit), 2021-2026
Table 20. Key Manufacturers Nitinol Revascularization Device Manufacturing Base and Headquarters
Table 21. Global Nitinol Revascularization Device Market Concentration Ratio (CR5)
Table 22. Key Market Entrant/Exit (2021-2025) – Drivers & Impact Analysis
Table 23. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 24. Global Nitinol Revascularization Device Sales Volume by Type (K Units), 2021-2026
Table 25. Global Nitinol Revascularization Device Sales Volume by Type (K Units), 2027-2032
Table 26. Global Nitinol Revascularization Device Revenue by Type (US$ Million), 2021-2026
Table 27. Global Nitinol Revascularization Device Revenue by Type (US$ Million), 2027-2032
Table 28. Global Nitinol Revascularization Device Sales Volume by Product Function (K Units), 2021-2026
Table 29. Global Nitinol Revascularization Device Sales Volume by Product Function (K Units), 2027-2032
Table 30. Global Nitinol Revascularization Device Revenue by Product Function (US$ Million), 2021-2026
Table 31. Global Nitinol Revascularization Device Revenue by Product Function (US$ Million), 2027-2032
Table 32. Global Nitinol Revascularization Device Sales Volume by Maximum Expanded Diameter (K Units), 2021-2026
Table 33. Global Nitinol Revascularization Device Sales Volume by Maximum Expanded Diameter (K Units), 2027-2032
Table 34. Global Nitinol Revascularization Device Revenue by Maximum Expanded Diameter (US$ Million), 2021-2026
Table 35. Global Nitinol Revascularization Device Revenue by Maximum Expanded Diameter (US$ Million), 2027-2032
Table 36. Technical Specifications by Key Product Type
Table 37. Global Nitinol Revascularization Device Sales by Application (K Units), 2021-2026
Table 38. Global Nitinol Revascularization Device Sales by Application (K Units), 2027-2032
Table 39. Nitinol Revascularization Device High-Growth Sectors Demand CAGR (2026-2032)
Table 40. Global Nitinol Revascularization Device Revenue by Application (US$ Million), 2021-2026
Table 41. Global Nitinol Revascularization Device Revenue by Application (US$ Million), 2027-2032
Table 42. Top Customers by Region
Table 43. Top Customers by Application
Table 44. North America Nitinol Revascularization Device Growth Accelerators and Market Barriers
Table 45. North America Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 46. North America Nitinol Revascularization Device Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 47. Europe Nitinol Revascularization Device Growth Accelerators and Market Barriers
Table 48. Europe Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Country: 2021 vs 2025 vs 2032 (US$ Million)
Table 49. Europe Nitinol Revascularization Device Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 50. Asia-Pacific Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 51. Asia-Pacific Nitinol Revascularization Device Sales (K Units) by Country (2021 vs 2025 vs 2032)
Table 52. Asia-Pacific Nitinol Revascularization Device Growth Accelerators and Market Barriers
Table 53. Southeast Asia Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Table 54. Central and South America Nitinol Revascularization Device Investment Opportunities and Key Challenges
Table 55. Central and South America Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 56. Middle East and Africa Nitinol Revascularization Device Investment Opportunities and Key Challenges
Table 57. Middle East and Africa Nitinol Revascularization Device Revenue Grow Rate (CAGR) by Country (2021 vs 2025 vs 2032) (US$ Million)
Table 58. Medtronic Corporation Information
Table 59. Medtronic Description and Major Businesses
Table 60. Medtronic Product Models, Descriptions and Specifications
Table 61. Medtronic Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 62. Medtronic Sales Value Proportion by Product in 2025
Table 63. Medtronic Sales Value Proportion by Application in 2025
Table 64. Medtronic Sales Value Proportion by Geographic Area in 2025
Table 65. Medtronic Nitinol Revascularization Device SWOT Analysis
Table 66. Medtronic Recent Developments
Table 67. Boston Scientific Corporation Information
Table 68. Boston Scientific Description and Major Businesses
Table 69. Boston Scientific Product Models, Descriptions and Specifications
Table 70. Boston Scientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 71. Boston Scientific Sales Value Proportion by Product in 2025
Table 72. Boston Scientific Sales Value Proportion by Application in 2025
Table 73. Boston Scientific Sales Value Proportion by Geographic Area in 2025
Table 74. Boston Scientific Nitinol Revascularization Device SWOT Analysis
Table 75. Boston Scientific Recent Developments
Table 76. Abbott Corporation Information
Table 77. Abbott Description and Major Businesses
Table 78. Abbott Product Models, Descriptions and Specifications
Table 79. Abbott Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 80. Abbott Sales Value Proportion by Product in 2025
Table 81. Abbott Sales Value Proportion by Application in 2025
Table 82. Abbott Sales Value Proportion by Geographic Area in 2025
Table 83. Abbott Nitinol Revascularization Device SWOT Analysis
Table 84. Abbott Recent Developments
Table 85. BD Corporation Information
Table 86. BD Description and Major Businesses
Table 87. BD Product Models, Descriptions and Specifications
Table 88. BD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 89. BD Sales Value Proportion by Product in 2025
Table 90. BD Sales Value Proportion by Application in 2025
Table 91. BD Sales Value Proportion by Geographic Area in 2025
Table 92. BD Nitinol Revascularization Device SWOT Analysis
Table 93. BD Recent Developments
Table 94. Cook Medical Corporation Information
Table 95. Cook Medical Description and Major Businesses
Table 96. Cook Medical Product Models, Descriptions and Specifications
Table 97. Cook Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 98. Cook Medical Sales Value Proportion by Product in 2025
Table 99. Cook Medical Sales Value Proportion by Application in 2025
Table 100. Cook Medical Sales Value Proportion by Geographic Area in 2025
Table 101. Cook Medical Nitinol Revascularization Device SWOT Analysis
Table 102. Cook Medical Recent Developments
Table 103. W. L. Gore & Associates Corporation Information
Table 104. W. L. Gore & Associates Description and Major Businesses
Table 105. W. L. Gore & Associates Product Models, Descriptions and Specifications
Table 106. W. L. Gore & Associates Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 107. W. L. Gore & Associates Recent Developments
Table 108. Cordis Corporation Information
Table 109. Cordis Description and Major Businesses
Table 110. Cordis Product Models, Descriptions and Specifications
Table 111. Cordis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 112. Cordis Recent Developments
Table 113. Teleflex Corporation Information
Table 114. Teleflex Description and Major Businesses
Table 115. Teleflex Product Models, Descriptions and Specifications
Table 116. Teleflex Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 117. Teleflex Recent Developments
Table 118. Terumo Corporation Information
Table 119. Terumo Description and Major Businesses
Table 120. Terumo Product Models, Descriptions and Specifications
Table 121. Terumo Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 122. Terumo Recent Developments
Table 123. Otsuka Holdings Corporation Information
Table 124. Otsuka Holdings Description and Major Businesses
Table 125. Otsuka Holdings Product Models, Descriptions and Specifications
Table 126. Otsuka Holdings Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 127. Otsuka Holdings Recent Developments
Table 128. Stryker Corporation Information
Table 129. Stryker Description and Major Businesses
Table 130. Stryker Product Models, Descriptions and Specifications
Table 131. Stryker Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 132. Stryker Recent Developments
Table 133. Johnson & Johnson Corporation Information
Table 134. Johnson & Johnson Description and Major Businesses
Table 135. Johnson & Johnson Product Models, Descriptions and Specifications
Table 136. Johnson & Johnson Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 137. Johnson & Johnson Recent Developments
Table 138. Acandis Corporation Information
Table 139. Acandis Description and Major Businesses
Table 140. Acandis Product Models, Descriptions and Specifications
Table 141. Acandis Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 142. Acandis Recent Developments
Table 143. Rapid Medical Corporation Information
Table 144. Rapid Medical Description and Major Businesses
Table 145. Rapid Medical Product Models, Descriptions and Specifications
Table 146. Rapid Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 147. Rapid Medical Recent Developments
Table 148. Vesalio Corporation Information
Table 149. Vesalio Description and Major Businesses
Table 150. Vesalio Product Models, Descriptions and Specifications
Table 151. Vesalio Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 152. Vesalio Recent Developments
Table 153. Wallaby Medical Corporation Information
Table 154. Wallaby Medical Description and Major Businesses
Table 155. Wallaby Medical Product Models, Descriptions and Specifications
Table 156. Wallaby Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 157. Wallaby Medical Recent Developments
Table 158. iVascular Corporation Information
Table 159. iVascular Description and Major Businesses
Table 160. iVascular Product Models, Descriptions and Specifications
Table 161. iVascular Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 162. iVascular Recent Developments
Table 163. Alvimedica Corporation Information
Table 164. Alvimedica Description and Major Businesses
Table 165. Alvimedica Product Models, Descriptions and Specifications
Table 166. Alvimedica Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 167. Alvimedica Recent Developments
Table 168. Balton Corporation Information
Table 169. Balton Description and Major Businesses
Table 170. Balton Product Models, Descriptions and Specifications
Table 171. Balton Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 172. Balton Recent Developments
Table 173. Meril Life Sciences Corporation Information
Table 174. Meril Life Sciences Description and Major Businesses
Table 175. Meril Life Sciences Product Models, Descriptions and Specifications
Table 176. Meril Life Sciences Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 177. Meril Life Sciences Recent Developments
Table 178. InspireMD Corporation Information
Table 179. InspireMD Description and Major Businesses
Table 180. InspireMD Product Models, Descriptions and Specifications
Table 181. InspireMD Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 182. InspireMD Recent Developments
Table 183. Gravity Medical Technology Corporation Information
Table 184. Gravity Medical Technology Description and Major Businesses
Table 185. Gravity Medical Technology Product Models, Descriptions and Specifications
Table 186. Gravity Medical Technology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 187. Gravity Medical Technology Recent Developments
Table 188. Zylox-Tonbridge Medical Technology Corporation Information
Table 189. Zylox-Tonbridge Medical Technology Description and Major Businesses
Table 190. Zylox-Tonbridge Medical Technology Product Models, Descriptions and Specifications
Table 191. Zylox-Tonbridge Medical Technology Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 192. Zylox-Tonbridge Medical Technology Recent Developments
Table 193. MicroPort Scientific Corporation Information
Table 194. MicroPort Scientific Description and Major Businesses
Table 195. MicroPort Scientific Product Models, Descriptions and Specifications
Table 196. MicroPort Scientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 197. MicroPort Scientific Recent Developments
Table 198. MicroPort NeuroScientific Corporation Information
Table 199. MicroPort NeuroScientific Description and Major Businesses
Table 200. MicroPort NeuroScientific Product Models, Descriptions and Specifications
Table 201. MicroPort NeuroScientific Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 202. MicroPort NeuroScientific Recent Developments
Table 203. Peijia Medical Corporation Information
Table 204. Peijia Medical Description and Major Businesses
Table 205. Peijia Medical Product Models, Descriptions and Specifications
Table 206. Peijia Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 207. Peijia Medical Recent Developments
Table 208. Skynor Medical Corporation Information
Table 209. Skynor Medical Description and Major Businesses
Table 210. Skynor Medical Product Models, Descriptions and Specifications
Table 211. Skynor Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 212. Skynor Medical Recent Developments
Table 213. Suzhou Zenith Vascular Corporation Information
Table 214. Suzhou Zenith Vascular Description and Major Businesses
Table 215. Suzhou Zenith Vascular Product Models, Descriptions and Specifications
Table 216. Suzhou Zenith Vascular Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 217. Suzhou Zenith Vascular Recent Developments
Table 218. TJWY Medical Corporation Information
Table 219. TJWY Medical Description and Major Businesses
Table 220. TJWY Medical Product Models, Descriptions and Specifications
Table 221. TJWY Medical Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026)
Table 222. TJWY Medical Recent Developments
Table 223. Key Raw Materials Distribution
Table 224. Raw Materials Key Suppliers
Table 225. Critical Raw Material Supplier Concentration (2025) & Risk Index
Table 226. Milestones in Production Technology Evolution
Table 227. Distributors List
Table 228. Market Trends and Market Evolution
Table 229. Market Drivers and Opportunities
Table 230. Market Challenges, Risks, and Restraints
Table 231. Research Programs/Design for This Report
Table 232. Key Data Information from Secondary Sources
Table 233. Key Data Information from Primary Sources

List of Figures
Figure 1. Nitinol Revascularization Device Product Picture
Figure 2. Global Nitinol Revascularization Device Market Size Growth Rate by Type, 2021 vs 2025 vs 2032 (US$ Million)
Figure 3. Laser-cut Product Picture
Figure 4. Braided Product Picture
Figure 5. Other Product Picture
Figure 6. Global Nitinol Revascularization Device Market Size Growth Rate by Product Function, 2021 vs 2025 vs 2032 (US$ Million)
Figure 7. Permanent Support Product Picture
Figure 8. Thrombus Retrieval Product Picture
Figure 9. Temporary Dilation Product Picture
Figure 10. Other Product Picture
Figure 11. Global Nitinol Revascularization Device Market Size Growth Rate by Maximum Expanded Diameter, 2021 vs 2025 vs 2032 (US$ Million)
Figure 12. ≤4 mm Product Picture
Figure 13. >4–6 mm Product Picture
Figure 14. >6–8 mm Product Picture
Figure 15. >8 mm Product Picture
Figure 16. Global Nitinol Revascularization Device Market Size Growth Rate by Application, 2021 vs 2025 vs 2032 (US$ Million)
Figure 17. Peripheral Artery Disease
Figure 18. Carotid Artery Disease
Figure 19. Acute Ischemic Stroke
Figure 20. Coronary Artery Disease
Figure 21. Other
Figure 22. Nitinol Revascularization Device Report Years Considered
Figure 23. Global Nitinol Revascularization Device Revenue, (US$ Million), 2021 vs 2025 vs 2032
Figure 24. Global Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 25. Global Nitinol Revascularization Device Revenue (CAGR) by Region: 2021 vs 2025 vs 2032 (US$ Million)
Figure 26. Global Nitinol Revascularization Device Revenue-Based Market Share by Region (2021-2032)
Figure 27. Global Nitinol Revascularization Device Sales (K Units), 2021-2032
Figure 28. Global Nitinol Revascularization Device Sales (CAGR) by Region: 2021 vs 2025 vs 2032 (K Units)
Figure 29. Global Nitinol Revascularization Device Sales Market Share by Region (2021-2032)
Figure 30. Top 5 and Top 10 Manufacturers Nitinol Revascularization Device Sales Volume Market Share in 2025
Figure 31. Global Nitinol Revascularization Device Revenue-Based Market Share Ranking (2025)
Figure 32. Tier Distribution by Revenue Contribution (2021 vs 2025)
Figure 33. Laser-cut Revenue-Based Market Share by Manufacturer in 2025
Figure 34. Braided Revenue-Based Market Share by Manufacturer in 2025
Figure 35. Other Revenue-Based Market Share by Manufacturer in 2025
Figure 36. Global Nitinol Revascularization Device Sales Volume-Based Market Share by Type (2021-2032)
Figure 37. Global Nitinol Revascularization Device Revenue-Based Market Share by Type (2021-2032)
Figure 38. Global Nitinol Revascularization Device ASP by Type (US$/Unit), 2021-2032
Figure 39. Global Nitinol Revascularization Device Sales Volume-Based Market Share by Product Function (2021-2032)
Figure 40. Global Nitinol Revascularization Device Revenue-Based Market Share by Product Function (2021-2032)
Figure 41. Global Nitinol Revascularization Device ASP by Product Function (US$/Unit), 2021-2032
Figure 42. Global Nitinol Revascularization Device Sales Volume-Based Market Share by Maximum Expanded Diameter (2021-2032)
Figure 43. Global Nitinol Revascularization Device Revenue-Based Market Share by Maximum Expanded Diameter (2021-2032)
Figure 44. Global Nitinol Revascularization Device ASP by Maximum Expanded Diameter (US$/Unit), 2021-2032
Figure 45. Global Nitinol Revascularization Device Sales Market Share by Application (2021-2032)
Figure 46. Global Nitinol Revascularization Device Revenue-Based Market Share by Application (2021-2032)
Figure 47. Global Nitinol Revascularization Device ASP by Application (US$/Unit), 2021-2032
Figure 48. North America Nitinol Revascularization Device Sales YoY (K Units), 2021-2032
Figure 49. North America Nitinol Revascularization Device Revenue YoY (US$ Million), 2021-2032
Figure 50. North America Top 5 Manufacturers Nitinol Revascularization Device Sales Revenue (US$ Million) in 2025
Figure 51. North America Nitinol Revascularization Device Sales Volume (K Units) by Application (2021-2032)
Figure 52. North America Nitinol Revascularization Device Sales Revenue (US$ Million) by Application (2021-2032)
Figure 53. US Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 54. Canada Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 55. Mexico Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 56. Europe Nitinol Revascularization Device Sales YoY (K Units), 2021-2032
Figure 57. Europe Nitinol Revascularization Device Revenue YoY (US$ Million), 2021-2032
Figure 58. Europe Top 5 Manufacturers Nitinol Revascularization Device Sales Revenue (US$ Million) in 2025
Figure 59. Europe Nitinol Revascularization Device Sales Volume (K Units) by Application (2021-2032)
Figure 60. Europe Nitinol Revascularization Device Sales Revenue (US$ Million) by Application (2021-2032)
Figure 61. Germany Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 62. France Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 63. U.K. Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 64. Italy Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 65. Russia Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 66. Asia-Pacific Nitinol Revascularization Device Sales YoY (K Units), 2021-2032
Figure 67. Asia-Pacific Nitinol Revascularization Device Revenue YoY (US$ Million), 2021-2032
Figure 68. Asia-Pacific Top 8 Manufacturers Nitinol Revascularization Device Sales Revenue (US$ Million) in 2025
Figure 69. Asia-Pacific Nitinol Revascularization Device Sales Volume (K Units) by Application (2021-2032)
Figure 70. Asia-Pacific Nitinol Revascularization Device Sales Revenue (US$ Million) by Application (2021-2032)
Figure 71. Indonesia Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 72. Japan Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 73. South Korea Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 74. China Taiwan Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 75. India Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 76. Central and South America Nitinol Revascularization Device Sales YoY (K Units), 2021-2032
Figure 77. Central and South America Nitinol Revascularization Device Revenue YoY (US$ Million), 2021-2032
Figure 78. Central and South America Top 5 Manufacturers Nitinol Revascularization Device Sales Revenue (US$ Million) in 2025
Figure 79. Central and South America Nitinol Revascularization Device Sales Volume (K Units) by Application (2021-2032)
Figure 80. Central and South America Nitinol Revascularization Device Sales Revenue (US$ Million) by Application (2021-2032)
Figure 81. Brazil Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 82. Argentina Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 83. Middle East, and Africa Nitinol Revascularization Device Sales YoY (K Units), 2021-2032
Figure 84. Middle East and Africa Nitinol Revascularization Device Revenue YoY (US$ Million), 2021-2032
Figure 85. Middle East and Africa Top 5 Manufacturers Nitinol Revascularization Device Sales Revenue (US$ Million) in 2025
Figure 86. Middle East and Africa Nitinol Revascularization Device Sales Volume (K Units) by Application (2021-2032)
Figure 87. Middle East and Africa Nitinol Revascularization Device Sales Revenue (US$ Million) by Application (2021-2032)
Figure 88. GCC Countries Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 89. Turkey Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 90. Egypt Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 91. South Africa Nitinol Revascularization Device Revenue (US$ Million), 2021-2032
Figure 92. Nitinol Revascularization Device Industry Chain Mapping
Figure 93. Regional Nitinol Revascularization Device Manufacturing Base Distribution (%)
Figure 94. Global Nitinol Revascularization Device Production Market Share by Region (2021-2032)
Figure 95. Nitinol Revascularization Device Production Process
Figure 96. Regional Nitinol Revascularization Device Production Cost Structure
Figure 97. Channels of Distribution (Direct Vs Distribution)
Figure 98. Bottom-up and Top-down Approaches for This Report
Figure 99. Data Triangulation
Figure 100. Key Executives Interviewed